Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts

Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (NNOX), signed a 3-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution. Separately, it partnered with Intel to optimize its AI framework for local hospital hardware. The company aims to leverage additional anatomical data from CT scans to support clinical evaluations. According to Nanox, 86,000 vertebral fragility fractures occur annually in the UK, many undiagnosed.

Original reporting
Published Sep 29, 2026, 4:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 5:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts — source image
Decision brief

The 30-second read

$NNOXBullishMed
01

Why it matters

The announcements broaden Nanox's market footprint and could improve margins by reducing cloud‑dependency, but the financial magnitude remains unclear.

02

Market read

First report of a UK reseller deal and Intel collaboration for Nanox, offering modest upside potential for the stock.

03

What to watch

Potential regulatory or reimbursement hurdles in the UK could delay commercial rollout.

Relevance 5/10Novelty 5/10Timing: today

Background

Nanox.AI is expanding its AI imaging analytics platform through a new reseller partnership and a hardware optimization project with Intel.

Company-level read

Ticker impact

$NNOXBullishMedium confidence
Context

Nanox.AI signed an exclusive three‑year UK reseller agreement with Vertec Scientific and announced an Intel optimization project for local AI inference.

Expected impact

likely modest upside as the market prices in the new reseller deal and AI‑hardware collaboration

Evidence & confidence

First disclosure of a multi‑year reseller agreement and a technical partnership, but no disclosed dollar amount limits material impact.

Market effects

May signal growing demand for AI‑enabled imaging solutions in the UK healthcare market.

Could lift other med‑tech firms with UK exposure.

Limited to niche AI‑health segment; broader market impact modest.

Counterpoint

The contracts may be too small to materially affect revenue, and execution risk could limit upside.

Key entities

  • Nanox.AI

    Medical imaging analytics subsidiary of Nano‑X Imaging Ltd.

  • Vertec Scientific

    UK-based distributor of medical imaging solutions.

  • Intel

    Technology partner providing local inference capability.

Related articles

$NNOXMed

Nano X Imaging Ltd (NNOX) (Q2 2026) Earnings Call Highlights: Re

Nano X Imaging Ltd (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, driven by growth in teleradiology services and new partnerships. The company also announced operational streamlining and cost reductions. However, NNOX recorded a $40.7 million impairment charge, a significant decrease in cash position, and a widened net loss of $55.5 million. Management expects revenue traction in the coming months and potential market expansion due to new reimbursement codes.

$NNOXHigh

Nano-X Imaging Ltd. (NNOX): Financial results for Q2 2026

Nano-X Imaging Ltd. (NNOX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates Management to host conference call and webcast on Wednesday, September 9, 2026 at 8:30 AM ET PETACH TIKVA, Israel — September 9, 2026 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or

$NNOXMed

NANO-X IMAGING LTD: Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom

Nanox Imaging Ltd (NASDAQ: NNOX) said its subsidiary Nanox AI entered an exclusive UK sales reseller agreement with Vertec Scientific for commercialization of Nanox.AI bone solution (HealthOST). The initial three-year term requires Vertec to meet minimum annual license commitments. HealthOST is FDA-cleared and UKCA/CE-marked and was recommended by NICE in Nov 2025 for NHS use.

$BDTXHighAI 9/10

Raymond James reiterates Black Diamond stock rating on trial data

Raymond James reiterated an Outperform rating and $11 price target for Black Diamond Therapeutics (BDTX), citing positive Phase 2 trial data for silevertinib in non-small cell lung cancer. The stock is near its 52-week low of $1.60. The FDA has provided feedback on the Phase 3 trial design, and the company reported Q3 2026 earnings. Stifel raised its price target to $14, maintaining a Buy rating.

$NVDAMed

Goldman Sachs Says Chip Selloff Went Too Far, Flags Nvidia, Broadcom and AMD as Buys

Goldman Sachs believes the semiconductor selloff has been excessive, highlighting Nvidia (NVDA), Broadcom (AVGO), and AMD (AMD) as attractive investment opportunities. The firm notes that these stocks are now in oversold territory, with compelling valuations even under pessimistic scenarios. The call comes after a significant market downturn, with the Philadelphia Semiconductor Index down 21% over the past month.